BrightSpring Health Services, Inc. Common Stock
BTSG
$60.73
-1.14%
BrightSpring Health Services, Inc. is a home and community-based healthcare services platform that delivers complementary pharmacy and provider services to complex patients across Medicare, Medicaid, and commercially insured populations. The company operates through two primary segments: Pharmacy Solutions and Provider Services, with the former generating the majority of revenue. As a relatively recent IPO (listed January 2024), BrightSpring has quickly established itself as a key player in the healthcare services space, focusing on high-acuity, complex patient populations. The current investor narrative centers on the company's robust revenue growth, strategic divestitures to streamline operations, and its ability to capitalize on the secular shift toward home and community-based care, though its high debt load and thin margins remain key points of debate.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$60.73
Related headlines
Investment Opinion: Should I buy BTSG Today?
Based on the data, BTSG is rated a Buy. The consensus is Strong Buy with an average target of $78.94, implying 30% upside, and the company's accelerating revenue growth and margin expansion support this view. The thesis is that BTSG is a high-growth healthcare services platform benefiting from secular shifts to home-based care, with improving profitability that justifies its premium valuation.
Sign up to view all
BTSG 12-Month Price Forecast
The AI model assesses BTSG as bullish with medium confidence. The company's accelerating revenue growth and improving profitability are strong positive signals, and the analyst community is overwhelmingly supportive. However, the high debt and thin margins introduce uncertainty, and the stock's high beta makes it vulnerable to market volatility. The model would upgrade to high confidence if net margins exceed 5% and revenue growth remains above 25% for two consecutive quarters. Conversely, a downgrade to neutral would occur if revenue growth falls below 15% or net margin drops below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +30.0% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
BrightSpring is covered by 17 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.18 on a 1-5 scale, where 1 is Strong Buy). The average target price is $78.94, implying an upside of 30.0% from the current price of $60.73. The analyst sentiment is overwhelmingly bullish, with no Hold or Sell ratings, and recent actions from major firms like Morgan Stanley, KeyBanc, and Wells Fargo have all been Overweight or Buy, indicating a positive outlook.
Bulls vs Bears: BTSG Investment Factors
BrightSpring presents a compelling growth story with accelerating revenue, improving profitability, and unanimous analyst bullishness, but it is tempered by high leverage, thin margins, and a valuation premium. The bull case currently holds stronger evidence given the 25.6% revenue growth and net margin expansion from 0.9% to 4.1% in just three quarters, which supports the 30% upside to the average target. The central tension is whether the company can sustain its margin improvement and growth trajectory to justify a 39.8x trailing PE, or if competitive pressures and debt costs will cap profitability. If margins continue to expand and revenue growth stays above 20%, the stock likely re-rates higher; if not, the high beta and valuation could lead to a sharp correction.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue surged 25.6% YoY to $3.61B, up from $2.88B in Q1 2025, with sequential growth from $3.55B in Q4 2025. This acceleration is driven by the Pharmacy Solutions segment, reflecting strong demand for specialty pharmacy services.
- Dramatic Profitability Improvement: Net income jumped from $28.2M in Q2 2025 to $148.8M in Q1 2026, with net margin expanding from 0.9% to 4.1% over the same period. EPS of $0.73 in Q1 2026 marks a significant inflection toward sustained profitability.
- Overwhelming Analyst Support: All 17 analysts rate BTSG a Strong Buy (mean 1.18), with an average target of $78.94, implying 30% upside. No Hold or Sell ratings exist, and recent actions from Morgan Stanley, KeyBanc, and Wells Fargo are all Overweight/Buy.
- Strategic Divestitures Streamline Focus: The sale of ResCare Community Living to Sevita in March 2026 sharpens focus on core Provider Services and reduces operational complexity. This divestiture is expected to improve margins and allow management to concentrate on higher-growth pharmacy and specialty services.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity stands at 1.44, indicating significant leverage. Interest expense of $38.6M in Q1 2026 consumes a large portion of operating income ($121.4M), leaving limited cushion for downturns or rising rates.
- Thin Gross and Operating Margins: Gross margin is only 13.3% and operating margin is 3.4%, reflecting a low-margin healthcare services model. This leaves little room for error and makes profitability highly sensitive to cost inflation or reimbursement cuts.
- Valuation Premium to Historical Norms: Trailing PE of 39.8x is well above the historical median of ~27x, and forward PE of 26.7x still implies high growth expectations. If earnings growth disappoints, multiple compression could be severe.
- High Beta Amplifies Downside Risk: With a beta of 1.85, BTSG is 85% more volatile than the market. In a market selloff, the stock could fall significantly more than the S&P 500, as evidenced by its max drawdown of -21.5% in the past year.
BTSG Technical Analysis
BrightSpring's stock is in a powerful long-term uptrend, with a 1-year price change of +152.1%, dramatically outperforming the S&P 500's +18.7% over the same period. The current price of $60.73 sits at 82.4% of its 52-week range (between $23.69 low and $73.75 high), indicating the stock is trading near the upper end of its historical range, which typically reflects strong momentum and investor optimism, though it also raises the risk of overextension. The stock's beta of 1.85 implies it is 85% more volatile than the market, making it a high-beta play that amplifies both upside and downside moves.
Beta
1.85
1.85x market volatility
Max Drawdown
-21.5%
Largest decline past year
52-Week Range
$24-$74
Price range past year
Annual Return
+152.1%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | -0.4% |
| 3m | +5.8% | +4.2% |
| 6m | +46.4% | +13.7% |
| 1y | +152.1% | +19.0% |
| ytd | +58.2% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
BrightSpring's revenue trajectory is robustly accelerating, with Q1 2026 revenue of $3.61 billion, up 25.6% year-over-year, and sequential growth from $3.55 billion in Q4 2025 and $3.33 billion in Q3 2025. This growth is driven by the Pharmacy Solutions segment, which benefits from increased demand for specialty pharmacy services, while the Provider Services segment is being streamlined through divestitures like the sale of ResCare Community Living. The company's net income has also improved dramatically, rising from $28.2 million in Q2 2025 to $148.8 million in Q1 2026, with EPS of $0.73, reflecting a net margin of 4.1% in Q1 2026, up from 0.9% in Q2 2025, indicating a clear trajectory toward profitability.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
13.3%
Latest Quarter
Free Cash Flow
$412118000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Given that BrightSpring is profitable (net income of $148.8 million in Q1 2026), the PE ratio is the most appropriate valuation metric. The trailing PE stands at 39.8x, while the forward PE is 26.7x, implying the market expects significant earnings growth (approximately 49% increase) over the next year. The stock's PS ratio of 0.59x is notably lower than the industry average of 1.0x, suggesting the market is pricing in lower margins relative to peers, but the EV/Sales ratio of 1.01x is more in line with the sector. Historically, the trailing PE has ranged from negative values in 2023 to as high as 53.2x in Q4 2024, and the current 39.8x is above the historical median of around 27x, indicating the stock is trading at a premium to its own historical valuation, reflecting improved profitability and growth expectations.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, BTSG carries a debt-to-equity ratio of 1.44, and interest expense of $38.6M in Q1 2026 consumed about 32% of operating income ($121.4M), leaving limited coverage. The company's gross margin of 13.3% and operating margin of 3.4% are razor-thin, making it vulnerable to any cost inflation or reimbursement rate cuts. While free cash flow is positive at $412M TTM, the high leverage and low margins mean that a modest downturn in revenue or a rise in interest rates could quickly erode profitability, as seen in Q2 2025 when net income was only $28.2M on $3.15B revenue (0.9% margin).